Successful treatment of Grover's disease with upadacitinib: A case report.

IF 0.6 Q3 MEDICINE, GENERAL & INTERNAL

SAGE Open Medical Case Reports Pub Date : 2026-08-16 eCollection Date: 2026-01-01 DOI:10.1177/2050313X261463981

Eshan Arora, Rylee Oosterhuis, Ashley E Sutherland

{"title":"Successful treatment of Grover's disease with upadacitinib: A case report.","authors":"Eshan Arora, Rylee Oosterhuis, Ashley E Sutherland","doi":"10.1177/2050313X261463981","DOIUrl":null,"url":null,"abstract":"<p><p>Transient acantholytic dermatosis, also known as Grover's disease, is an acquired pruritic eruption commonly refractory to conventional therapies. We report a case of a 76-year-old male with Grover's disease presenting with persistent pruritus and skin lesions despite multiple treatments. Upadacitinib 15 mg once daily was initiated off-label and the patient reported marked improvement in pruritus within 2 days of treatment and substantial reduction in lesion burden after 1 month. The etiology of Grover's disease is unclear but is believed to be due in part to occlusion and damage to the sweat glands. Emerging responses to immunomodulatory therapies suggest immune dysregulation may contribute to select cases of Grover's disease. Upadacitinib, a selective Janus kinase 1 inhibitor, reduces pruritus and inflammation-associated cytokine signaling and represents a plausible therapeutic strategy. To our knowledge, this is the first reported case of Grover's disease successfully treated with Janus kinase inhibition.</p>","PeriodicalId":21418,"journal":{"name":"SAGE Open Medical Case Reports","volume":"14 ","pages":"2050313X261463981"},"PeriodicalIF":0.6000,"publicationDate":"2026-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13478646/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"SAGE Open Medical Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/2050313X261463981","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Transient acantholytic dermatosis, also known as Grover's disease, is an acquired pruritic eruption commonly refractory to conventional therapies. We report a case of a 76-year-old male with Grover's disease presenting with persistent pruritus and skin lesions despite multiple treatments. Upadacitinib 15 mg once daily was initiated off-label and the patient reported marked improvement in pruritus within 2 days of treatment and substantial reduction in lesion burden after 1 month. The etiology of Grover's disease is unclear but is believed to be due in part to occlusion and damage to the sweat glands. Emerging responses to immunomodulatory therapies suggest immune dysregulation may contribute to select cases of Grover's disease. Upadacitinib, a selective Janus kinase 1 inhibitor, reduces pruritus and inflammation-associated cytokine signaling and represents a plausible therapeutic strategy. To our knowledge, this is the first reported case of Grover's disease successfully treated with Janus kinase inhibition.

查看原文本刊更多论文

upadacitinib成功治疗Grover病1例报告。

一过性棘囊性皮肤病，也被称为格罗弗病，是一种获得性瘙痒性皮疹，通常难以常规治疗。我们报告一个76岁的男性格罗弗病的情况下，尽管多次治疗持续瘙痒和皮肤病变。Upadacitinib 15mg，每日一次，在标签外开始治疗，患者报告在治疗2天内瘙痒明显改善，1个月后病变负担显著减轻。格罗弗氏病的病因尚不清楚，但据信部分原因是由于汗腺闭塞和损伤。对免疫调节疗法的新反应表明，免疫失调可能导致格罗弗病的某些病例。Upadacitinib是一种选择性Janus激酶1抑制剂，可减少瘙痒和炎症相关的细胞因子信号，是一种可行的治疗策略。据我们所知，这是第一例报道的格罗弗病成功治疗与Janus激酶抑制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

SAGE Open Medical Case Reports MEDICINE, GENERAL & INTERNAL-

CiteScore

0.60

自引率

0.00%

发文量

320

审稿时长

8 weeks

期刊介绍： SAGE Open Medical Case Reports (indexed in PubMed Central) is a peer reviewed, open access journal. It aims to provide a publication home for short case reports and case series, which often do not find a place in traditional primary research journals, but provide key insights into real medical cases that are essential for physicians, and may ultimately help to improve patient outcomes. SAGE Open Medical Case Reports does not limit content due to page budgets or thematic significance. Papers are subject to rigorous peer review and are selected on the basis of whether the research is sound and deserves publication. By virtue of not restricting papers to a narrow discipline, SAGE Open Medical Case Reports facilitates the discovery of the connections between papers, whether within or between disciplines. Case reports can span the full spectrum of medicine across the health sciences in the broadest sense, including: Allergy/Immunology Anaesthesia/Pain Cardiovascular Critical Care/ Emergency Medicine Dentistry Dermatology Diabetes/Endocrinology Epidemiology/Public Health Gastroenterology/Hepatology Geriatrics/Gerontology Haematology Infectious Diseases Mental Health/Psychiatry Nephrology Neurology Nursing Obstetrics/Gynaecology Oncology Ophthalmology Orthopaedics/Rehabilitation/Occupational Therapy Otolaryngology Palliative Medicine Pathology Pharmacoeconomics/health economics Pharmacoepidemiology/Drug safety Psychopharmacology Radiology Respiratory Medicine Rheumatology/ Clinical Immunology Sports Medicine Surgery Toxicology Urology Women''s Health.